TerminatedPhase 3NCT03403751
Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury
Studying Necrotizing soft tissue infection
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Atox Bio Ltd
- Principal Investigator
- Azra Bihorac, MD, MDUniversity of Florida Health
- Intervention
- Reltecimod 0.5 mg/kg(drug)
- Enrollment
- 58 enrolled
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2018 – 2019
Study locations (30)
- Maricopa Medical Center, Phoenix, Arizona, United States
- Banner University Medical Center, Tucson, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- University of California, Davis Medical Center, Sacramento, California, United States
- UCSD Medical Center, San Diego, California, United States
- Harbor-UCLA Medical Center, Torrance, California, United States
- UCH-Memorial Health System, Colorado Springs, Colorado, United States
- University of Colorado Hospital, Denver, Colorado, United States
- Yale New Haven Hospital, New Haven, Connecticut, United States
- Washington Hospital Center, Washington D.C., District of Columbia, United States
- UF Health Shands Hospital, Gainesville, Florida, United States
- University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
- University of Kentucky, Lexington, Kentucky, United States
- LSU Health Science Center, New Orleans, Louisiana, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03403751 on ClinicalTrials.govOther trials for Necrotizing soft tissue infection
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07107555Necrotizing Soft Tissue InfectionsEuropean Society for Trauma and Emergency Surgery
- RECRUITINGNANCT07120386Irrigating vs Traditional Negative Pressure Wound Therapy to Treat Necrotizing Soft Tissue InfectionsHealthPartners Institute
- RECRUITINGNANCT06857708The Management of Necrotizing Soft Tissue Infection Wounds With Cytal® Wound Matrix and MicroMatrix®Benjamin T. Miller
- RECRUITINGNANCT03482245The Role of Circadian Clock Proteins in Innate and Adaptive ImmunityWashington University School of Medicine
- RECRUITINGNCT06002607Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue InfectionsUniversity of California, Irvine
- RECRUITINGNCT07359651FATAL-NSTI Study (Factors Associated With In-hospital mortALity in NSTI).University of Cagliari